Skip to main content
. 2022 Oct 24;14(20):8140–8149. doi: 10.18632/aging.204354

Figure 3.

Figure 3

Hypothetical rapamycin treatment in humans for maximal longevity. Started early in post-development (for example, at 21 yo), low doses of rapamycin decelerate progression of pre-diseases (slow aging). Side effects are more undesirable at younger ages and doses should be low. Doses are gradually increased, to avoid rapamycin adaptation and to maximize therapeutic potential.